Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial

Conclusions
Sustained reductions in TSC-associated treatment-refractory seizures over time were achieved with adjunctive everolimus. The safety profile was consistent with the core phase with no new safety concerns.

Classification of evidence
This study provides Class IV evidence that long-term everolimus therapy reduces SF in patients with TSC-associated treatment-refractory seizures.

Source: Neurology Clinical Practice - October 15, 2018 Category: Neurology Authors: Franz, D. N., Lawson, J. A., Yapici, Z., Ikeda, H., Polster, T., Nabbout, R., Curatolo, P., de Vries, P. J., Dlugos, D. J., Voi, M., Fan, J., Vaury, A., Pelov, D., French, J. A. Tags: Class IV, All Epilepsy/Seizures Research Source Type: research